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OBJECTIVES: To evaluate doctors’ adherence to Malaysian Clinical Practice Guide-
lines on management of hypertension (CPG 2008) in patients with cardiovascular
disease, and factors associated with guidelines adherence and hypertension
control. METHODS: This was a cross sectional study conducted at outpatient car-
diology clinic of Penang Hospital. A total of 13 doctors practicing in the clinic were
enrolled in the study. Prescriptions written by each doctor to 25 established hyper-
tensive patients with cardiovascular disease (total 325) were noted on visit 1 along
with patients’ demographic and clinical data. Implicit review of patients’ medical
record was conducted to find acceptable rationale for nonadherence to guidelines.
The prescriptions written were categorized either as adherent or non-adherent to
CPG (2008). Two hundred sixty of the enrolled 320 patients (20 out of 25 patients
enrolled per doctor) were followed for another one visit. Blood pressure readings
noted on visit 2 were related to prescriptions written on visit 1. SPSS 16 was used for
data analysis. RESULTS: One hundred ninety-one (73.5%) patients received guide-
lines compliant pharmacotherapy. CPG compliance had statistically significant
weak negative association with left ventricular hypertrophy (LVH) ( -0.241,
P0.01), and diabetes ( -0.228, P0.01). One hundred fifty-four (59.2 %) patients
were on goal BP. Hypertension control had statistically significant weak positive
association with guidelines adherence (0.175, P0.01), and Angiotensin con-
verting enzyme inhibitors (0.195, P0.01), while weak negative association with
diabetes mellitus (-0.148, P0.017), left ventricular hypertrophy (LVH) (-
0.153, P0.017) and monotherapy (-0.168, P0.01). CONCLUSIONS: Adherence
to guidelines resulted in better hypertension control. Overall prescribing practices
were in fair compliance with guidelines but room for further improvement is still
present. Doctors’ poor adherence to guidelines in patients with diabetes mellitus
and LVH needs further probing and focus in future.
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OBJECTIVES: To evaluate impact of guidelines adherence and factors associated
with hypertension control METHODS: This was a cross sectional study conducted
at Penang Hospital. Twenty-six doctors; 13 from cardiology, 5 from nephrology and
4 from hypertension and diabetic clinics each were enrolled in the study. Prescrip-
tions written by each doctor to 25 established hypertensive patients (total of 650)
were noted on visit 1 along with patients’ demographic and clinical data. Implicit
review of patients’ medical record was conducted to find acceptable rationale for
non adherence to guidelines. The prescriptions written were categorized either as
compliant or non-compliant to Malaysian Clinical Practice Guidelines on manage-
ment of hypertension (CPG 2008). Five hundred and twenty of the enrolled 650
patients (20 out of 25 patients enrolled per doctor) were followed for another one
visit. BP readings noted on visit 2 were related to the prescriptions written on visit
1. SPSS 16 was used for data analysis. RESULTS: Three hundred forty-nine (67.1%)
patients received guidelines compliant pharmacotherapy. Two hundred sixty-five
(51%) patients were on goal BP on visit 2. Hypertension control had statistically
significant weak positive association with CPG adherence (0.14, P0.01), greater
number of antihypertensive drugs (Effect size 0.11, P0.01), cardiovascular dis-
ease (0.127, P0.01) and management of hypertension at cardiology clinic
(0.13, P0.01), while moderate positive association with Angiotensin converting
enzyme inhibitors (0.20, P0.01). Statistically significant weak negative associ-
ation was observed between hypertension control and diabetes mellitus ( -0.17,
P0.01), renal disease ( -0.17, P 0.01), and management of hypertension at
nephrology ( -0.10, P0.02) and diabetic clinics ( -0.14, P0.01).
CONCLUSIONS: Guidelines adherent pharmacotherapy resulted in better hyper-
tension control. Suboptimal BP control in patients with diabetes mellitus, renal
disease and treated at nephrology and diabetic clinics needs focus and further
probing.
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OBJECTIVES: To conduct cost-effectiveness analysis of bosentan and sildenafil
compared with standard therapy (ST, i.e. calcium channel blockers and warfarin) in
treatment of primary pulmonary arterial hypertension (PAH) in Russian
Federation.METHODS:We undertook cost-effectiveness analysis of bosentan (62.5
mg bid during first 4 weeks and 125 mg bid further) and sildenafil (25 mg tid) and
estimated incremental cost-effectiveness ratios (ICER) for each drug vs ST. A cohort
of 20 patients with PAH, functional class (FC) III was simulated in a model. The
patients either received bosentanST, or sildenafilST, or ST only. The number of
patients whose health state improves by one FC was considered a criterion of
efficacy. Costs of hospitalization, standard therapy medications, and investiga-
tional drugs were calculated in the model. Data on clinical efficacy of bosentan,
sildenafil, and ST were extracted from clinical trials. Patient’s treatment scheme
considered in the model was based on the results of peer interview. RESULTS: In
our model treatment with bosentan was the most effective: 9 of 20 patients versus
6 and 2 of 20 patients who had improved by one FC with bosentan, sildenafil and ST,
respectively. Also, the highest overall costs were in the bosentan group: 1,163,948
USD per 20 patients per year. Overall costs in case of sildenafil and standard ther-
apy were 724,520 and 57,969 USD per group per year, respectively. However, com-
parison of bosentan with ST yielded lower ICER than comparison of sildenafil with
ST: 157,997 and 166,638 USD per one patient with improvement by one FC, respec-
tively. Trend in the results remained the same with bosentan price up to 4400 USD
per pack in one-way sensitivity analysis. CONCLUSIONS: The results of this study
suggest that treatment of FC III PAH with bosentan is more preferable than treat-
ment with sildenafil.
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OBJECTIVES: The objective of this study was to compare, by means of an indirect
treatment comparison (ITC), the efficacy and safety of a bivalirudin-based antico-
agulation strategy to heparin monotherapy, in patients with ST-elevation myocar-
dial infarction (STEMI) intended for primary percutaneous coronary intervention
(PPCI). METHODS: A systematic literature review was performed using Embase,
Medline, Medline In-Progress, and the Cochrane Library to identify randomised
controlled trials (RCTs) to build a network of bivalirudin and heparin monotherapy
strategies in STEMI patients using a common reference strategy (heparin with
glycoprotein IIb/IIIa inhibitor (heparinGPI)). Identified data were analysed using
fixed and random effects Bayesian ITC. A base-case analysis was constructed from
intention-to-treat populations in the RCTs. Outcomes (mortality, stroke, MI, isch-
aemic target vessel revascularisation (I-TVR), major adverse cardiovascular events,
TIMI major and minor bleeding) were evaluated at 30-days and 1 year. RESULTS:
Eight RCTs were identified for inclusion in the ITC. At 30-days the bivalirudin-based
strategy was expected to result in fewer deaths (odds ratio [OR]:0.55; credible in-
terval [CrL]:0.32,0.95) compared to a heparin monotherapy, which was sustained at
1-year (OR:0.50; CrL:0.31, 0.79). Other outcomes [stroke (OR:0.88; CrL:0.37, 2.13); MI
(OR:0.79; CrL:0.40, 1.55); I-TVR (OR:0.75; CrL:0.38, 1.46); TIMI-major (OR:0.85; CrL:
0.47, 1.52) and TIMI-minor (OR:0.70; CrL:0.41, 1.18) bleeding] also tended favourably
towards bivalirudin. Consistent with the HORIZONS-AMI trial, when compared to a
heparinGPI-based strategy, a bivalirudin-based strategy resulted in fewer deaths
(30-days: OR:0.65; CrL:0.43, 1.00 and 1 year: OR:0.70; CrL:0.49, 0.97) and post-proce-
dural bleeding events (30-day TIMI-Major: OR:0.59; CrL:0.42, 0.83 and TIMI-minor:
OR:0.61; CrL:0.42, 0.87)), with comparable ischaemic protection. Scenario analyses
of RCT in/exclusion did not influence base-case findings. CONCLUSIONS: For
STEMI patients intended for PPCI, a bivalirudin-based strategy is expected to result
in fewer deaths at 30-days and 1-year, compared to using heparin monotherapy.
Other ischaemic and bleeding outcomes also tended towards improvement with
bivalirudin.
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OBJECTIVES: To evaluate prescription of guidelines recommended Angiotensin
converting enzyme inhibitors (ACE inhibitors) to established diabetic hypertensive
patients, and factors associated with prescription of ACE inhibitors and hyperten-
sion control. METHODS: This was a cross sectional study conducted at Penang
hospital. Prescriptions written to enrolled 250 established diabetic hypertensive
patients were noted on visit 1 along with demographic and clinical data. Implicit
review of the patients’ medical record was conducted to find acceptable rationale
for non prescription of ACE inhibitors. The enrolled patients were followed for
another one visit and their blood pressure (BP) readings noted on visit 2 were
related to prescriptions written on visit 1. Data was analyzed by SPSS 16. RESULTS:
Two hundred twenty five (86%) patients had multiple comorbidities. The most
prevalent comorbidity was cardiovascular disease (55.6%). Two hundred sixteen
patients (86.4%) were on polytherapy. ACE inhibitors were the most commonly
prescribed antihypertensive agents, prescribed to 158 (63.2%) patients followed by
Beta blockers prescribed to 154 (61.6%) patients. Ninety-two (36.8%) patients were
not on ACE inhibitors, among whom only 8 (8.6%) had contraindications to its use,
and 12 (13%) had diabetic nephropathy and were on guidelines recommended
Angiotensin receptor blockers. Chronic kidney disease had statistically significant
weak negative association with prescription of ACE inhibitors (-0.13, P0.03).
One hundred nine (43.6%) patients were on goal BP on visit 2. Hypertension control
had statistically significant moderate positive association with the use of ACE in-
hibitors (0.26, P0.01), and weak positive association with use of Aldosterone
antagonists (0.13, P0.04), polytherapy (0.17, P0.01), cardiovascular disease
(0.13, P0.03) and male gender (0.13, P0.03). CONCLUSIONS: Despite of
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